New Potential of Nilotinib in Cancer Treatment

Introduction to Nilotinib and Medulloblastoma

Recent findings indicate that nilotinib, a drug originally developed for leukemia, may hold promise for treating specific cancers, particularly Hedgehog-dependent medulloblastoma. This aggressive brain cancer accounts for approximately one-third of all pediatric brain malignancies. The Hedgehog (Hh) signaling pathway, particularly the Smoothened (SMO) component, plays a crucial role in normal embryonic development. However, abnormal activation of this pathway and excessive SMO production are linked to medulloblastoma and various other cancers. Additionally, the Hh pathway is vital for sustaining cancer stem cells, and its dysregulation can lead to chemotherapy and radiation resistance, resulting in cancer recurrence.

Limitations of Current Treatments

Current therapies for Hh-dependent cancers primarily target the SMO component. Unfortunately, SMO-specific antagonists often prove ineffective or lose efficacy over time, with only a minority of Hh-medulloblastoma patients responding positively to these medications. High rates of treatment resistance and relapse have prompted researchers to explore alternatives that can target multiple mechanisms within cancer cells associated with specific cancer subtypes.

Research Breakthroughs with Nilotinib

Discovery of Nilotinib’s Mechanism

A recent study published in PLOS ONE by a team of researchers in the United States sheds light on nilotinib’s ability to interact with SMOs in the Hh pathway—an action previously unrecognized. The researchers initially screened existing FDA-approved drugs with known anti-cancer properties, identifying candidates with characteristics akin to current SMO antagonists. Using three-dimensional docking models, they assessed these drugs for their capacity to bind to SMOs in the Hh pathway. Nilotinib emerged as a leading candidate with strong potential for attachment to SMOs, comparable to existing SMO-targeting therapies.

Effects of Nilotinib on Tumor Growth

The research team then evaluated nilotinib’s impact on tumor growth using mouse models. They injected human medulloblastoma tumors into the mice and treated them with nilotinib. Results indicated that the treated mice experienced reduced tumor growth without developing resistance to the treatment. Nilotinib demonstrated anti-SMO activity alongside its established anti-cancer properties, suggesting it operates through multiple mechanisms against cancer cells. This multi-target approach may render nilotinib a more effective option for managing Hh-dependent tumors compared to current SMO antagonists.

Future Directions for Nilotinib in Cancer Treatment

Potential Applications and Ongoing Research

These findings underscore nilotinib’s potential utility in treating specific Hh-dependent cancers, such as Hh-medulloblastoma. Although nilotinib has not yet been rigorously tested for Hh-dependent cancers, ongoing research is investigating its application in brain tumors. As an FDA-approved drug with a well-documented safety and efficacy profile, nilotinib is well-tolerated for long-term use. Given the current discoveries, researchers propose that nilotinib could serve as an ideal candidate for treating certain cancers, either as a standalone treatment or in conjunction with other anti-cancer therapies.

Citations

Chahal, K. K., Li, J., Kufareva, I., Parle, M., Durden, D. L., Wechsler-Reya, R. J., … Abagyan, R. (2019). Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma. Plos One, 14(9). doi: 10.1371/journal.pone.0214901

Leukemia drug shows promise for treating a childhood brain cancer. (2019, September 20). Retrieved from https://www.eurekalert.org/pub_releases/2019-09/uoc–lds092019.php

Image by Belova59 from Pixabay